Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain

Brain Res. 1994 Aug 29;655(1-2):153-60. doi: 10.1016/0006-8993(94)91609-8.


The 100,000 x g supernatant fraction of human brain contains endogenous inhibitors of antagonist binding to the muscarinic receptor. Significantly greater inhibition was observed with Alzheimer's than non-demented control supernatant fractions. Low molecular weight inhibitor was separated from larger inhibitor species by membrane dialysis (3,500 dalton cut-off). The activity of low molecular weight inhibitor was greatly increased by sulfhydryl reducing agents. While the low molecular weight inhibitor was stable to heat, acid and base for short time periods (< 20 min), it was inactivated by acid hydrolysis (50% loss after 16 h, 100% loss after 96 h). The low molecular weight inhibitor activity is elevated approximately three-fold in Alzheimer's brain. The low molecular weight inhibitor from Alzheimer's brain was found to be a non-competitive inhibitor. This is the first report of endogenous inhibitors in human brain of ligand binding to the muscarinic receptor and of increased inhibitor activity in Alzheimer's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alkaline Phosphatase / pharmacology
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology
  • Brain Chemistry / physiology
  • Female
  • Humans
  • Kinetics
  • Male
  • Mercaptoethanol / analogs & derivatives
  • Middle Aged
  • Molecular Weight
  • Muscarinic Antagonists / pharmacokinetics*
  • Nerve Tissue Proteins / biosynthesis
  • Quinuclidinyl Benzilate
  • Receptors, Muscarinic / metabolism*
  • Receptors, Muscarinic / physiology
  • Subcellular Fractions / drug effects
  • Subcellular Fractions / enzymology


  • Muscarinic Antagonists
  • Nerve Tissue Proteins
  • Receptors, Muscarinic
  • Mercaptoethanol
  • Quinuclidinyl Benzilate
  • 1,2-ethanedithiol
  • Alkaline Phosphatase